Characteristics of patients with prostate cancer who have initially been treated by hormone therapy in Japan: J-CaP surveillance

Hideyuki Akaza, Michiyuki Usami, Shiro Hinotsu, Osamu Ogawa, Susumu Kagawa, Tadaichi Kitamura, Taiji Tsukamoto, Seiji Naito, Yoshihiko Hirao, Masaru Murai, Hidetoshi Yamanaka

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Objective: Hormone therapy for prostate cancer has empirically prevailed in Japan. We planned to evaluate the trends and outcome of hormone therapy for establishing an adequate guideline. Methods: Patients with prostate cancer who were initially treated by hormone therapy were registered through the J-CaP registration system. This report summarizes the background factors. Results: From January 2001 to October 2003, 17 872 patients were registered from 395 institutes throughout Japan. The background factors of 17 312 patients were analyzed. The 17 872 patients were estimated as composing more than half of newly diagnosed prostate cancer patients in Japan. Of these, 22.9, 35.1, 32.9 and 8.6% belonged to T1, T2, T3 and T4, respectively. For the purposes of hormone therapy, 77.5% was primary hormone therapy. Neoadjuvant setting and adjuvant setting were 18.1 and 4.3%, respectively. About 60% of the hormone therapy was combined hormone therapy with LH-RHa plus anti-androgens. Conclusion: Irrespective of patients' age, TNM, stage of illness, or histological background, the majority of prostate cancer patients in Japan are receiving hormone therapy. It is necessary to evaluate whether this trend is merely a continuation of past experience of Japanese urologists or if there is a difference in the profile of effect and side-effect in the case of Japanese patients compared to therapy given in Westerners.

Original languageEnglish
Pages (from-to)329-336
Number of pages8
JournalJapanese Journal of Clinical Oncology
Volume34
Issue number6
DOIs
Publication statusPublished - Jun 1 2004
Externally publishedYes

Fingerprint

Prostatic Neoplasms
Japan
Hormones
Therapeutics
Androgens
Guidelines

Keywords

  • Endocrine therapy
  • Hormone therapy
  • Prostate cancer

ASJC Scopus subject areas

  • Oncology

Cite this

Characteristics of patients with prostate cancer who have initially been treated by hormone therapy in Japan : J-CaP surveillance. / Akaza, Hideyuki; Usami, Michiyuki; Hinotsu, Shiro; Ogawa, Osamu; Kagawa, Susumu; Kitamura, Tadaichi; Tsukamoto, Taiji; Naito, Seiji; Hirao, Yoshihiko; Murai, Masaru; Yamanaka, Hidetoshi.

In: Japanese Journal of Clinical Oncology, Vol. 34, No. 6, 01.06.2004, p. 329-336.

Research output: Contribution to journalArticle

Akaza, H, Usami, M, Hinotsu, S, Ogawa, O, Kagawa, S, Kitamura, T, Tsukamoto, T, Naito, S, Hirao, Y, Murai, M & Yamanaka, H 2004, 'Characteristics of patients with prostate cancer who have initially been treated by hormone therapy in Japan: J-CaP surveillance', Japanese Journal of Clinical Oncology, vol. 34, no. 6, pp. 329-336. https://doi.org/10.1093/jjco/hyh061
Akaza, Hideyuki ; Usami, Michiyuki ; Hinotsu, Shiro ; Ogawa, Osamu ; Kagawa, Susumu ; Kitamura, Tadaichi ; Tsukamoto, Taiji ; Naito, Seiji ; Hirao, Yoshihiko ; Murai, Masaru ; Yamanaka, Hidetoshi. / Characteristics of patients with prostate cancer who have initially been treated by hormone therapy in Japan : J-CaP surveillance. In: Japanese Journal of Clinical Oncology. 2004 ; Vol. 34, No. 6. pp. 329-336.
@article{af57b6c5ecfa49469f61e84ab45a5d41,
title = "Characteristics of patients with prostate cancer who have initially been treated by hormone therapy in Japan: J-CaP surveillance",
abstract = "Objective: Hormone therapy for prostate cancer has empirically prevailed in Japan. We planned to evaluate the trends and outcome of hormone therapy for establishing an adequate guideline. Methods: Patients with prostate cancer who were initially treated by hormone therapy were registered through the J-CaP registration system. This report summarizes the background factors. Results: From January 2001 to October 2003, 17 872 patients were registered from 395 institutes throughout Japan. The background factors of 17 312 patients were analyzed. The 17 872 patients were estimated as composing more than half of newly diagnosed prostate cancer patients in Japan. Of these, 22.9, 35.1, 32.9 and 8.6{\%} belonged to T1, T2, T3 and T4, respectively. For the purposes of hormone therapy, 77.5{\%} was primary hormone therapy. Neoadjuvant setting and adjuvant setting were 18.1 and 4.3{\%}, respectively. About 60{\%} of the hormone therapy was combined hormone therapy with LH-RHa plus anti-androgens. Conclusion: Irrespective of patients' age, TNM, stage of illness, or histological background, the majority of prostate cancer patients in Japan are receiving hormone therapy. It is necessary to evaluate whether this trend is merely a continuation of past experience of Japanese urologists or if there is a difference in the profile of effect and side-effect in the case of Japanese patients compared to therapy given in Westerners.",
keywords = "Endocrine therapy, Hormone therapy, Prostate cancer",
author = "Hideyuki Akaza and Michiyuki Usami and Shiro Hinotsu and Osamu Ogawa and Susumu Kagawa and Tadaichi Kitamura and Taiji Tsukamoto and Seiji Naito and Yoshihiko Hirao and Masaru Murai and Hidetoshi Yamanaka",
year = "2004",
month = "6",
day = "1",
doi = "10.1093/jjco/hyh061",
language = "English",
volume = "34",
pages = "329--336",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - Characteristics of patients with prostate cancer who have initially been treated by hormone therapy in Japan

T2 - J-CaP surveillance

AU - Akaza, Hideyuki

AU - Usami, Michiyuki

AU - Hinotsu, Shiro

AU - Ogawa, Osamu

AU - Kagawa, Susumu

AU - Kitamura, Tadaichi

AU - Tsukamoto, Taiji

AU - Naito, Seiji

AU - Hirao, Yoshihiko

AU - Murai, Masaru

AU - Yamanaka, Hidetoshi

PY - 2004/6/1

Y1 - 2004/6/1

N2 - Objective: Hormone therapy for prostate cancer has empirically prevailed in Japan. We planned to evaluate the trends and outcome of hormone therapy for establishing an adequate guideline. Methods: Patients with prostate cancer who were initially treated by hormone therapy were registered through the J-CaP registration system. This report summarizes the background factors. Results: From January 2001 to October 2003, 17 872 patients were registered from 395 institutes throughout Japan. The background factors of 17 312 patients were analyzed. The 17 872 patients were estimated as composing more than half of newly diagnosed prostate cancer patients in Japan. Of these, 22.9, 35.1, 32.9 and 8.6% belonged to T1, T2, T3 and T4, respectively. For the purposes of hormone therapy, 77.5% was primary hormone therapy. Neoadjuvant setting and adjuvant setting were 18.1 and 4.3%, respectively. About 60% of the hormone therapy was combined hormone therapy with LH-RHa plus anti-androgens. Conclusion: Irrespective of patients' age, TNM, stage of illness, or histological background, the majority of prostate cancer patients in Japan are receiving hormone therapy. It is necessary to evaluate whether this trend is merely a continuation of past experience of Japanese urologists or if there is a difference in the profile of effect and side-effect in the case of Japanese patients compared to therapy given in Westerners.

AB - Objective: Hormone therapy for prostate cancer has empirically prevailed in Japan. We planned to evaluate the trends and outcome of hormone therapy for establishing an adequate guideline. Methods: Patients with prostate cancer who were initially treated by hormone therapy were registered through the J-CaP registration system. This report summarizes the background factors. Results: From January 2001 to October 2003, 17 872 patients were registered from 395 institutes throughout Japan. The background factors of 17 312 patients were analyzed. The 17 872 patients were estimated as composing more than half of newly diagnosed prostate cancer patients in Japan. Of these, 22.9, 35.1, 32.9 and 8.6% belonged to T1, T2, T3 and T4, respectively. For the purposes of hormone therapy, 77.5% was primary hormone therapy. Neoadjuvant setting and adjuvant setting were 18.1 and 4.3%, respectively. About 60% of the hormone therapy was combined hormone therapy with LH-RHa plus anti-androgens. Conclusion: Irrespective of patients' age, TNM, stage of illness, or histological background, the majority of prostate cancer patients in Japan are receiving hormone therapy. It is necessary to evaluate whether this trend is merely a continuation of past experience of Japanese urologists or if there is a difference in the profile of effect and side-effect in the case of Japanese patients compared to therapy given in Westerners.

KW - Endocrine therapy

KW - Hormone therapy

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=6044231016&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=6044231016&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyh061

DO - 10.1093/jjco/hyh061

M3 - Article

C2 - 15333685

AN - SCOPUS:6044231016

VL - 34

SP - 329

EP - 336

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 6

ER -